2. Academic Validation
  3. Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis

Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis

  • Drug Des Devel Ther. 2019 May 6;13:1515-1525. doi: 10.2147/DDDT.S162913.
Veena Mathew 1,  Annabel K Wang 1 2
Affiliations

Affiliations

  • 1 Department of Neurology, UCI ALS and Neuromuscular Center, University of California, Irvine, Orange, CA, USA, akwang@uci.edu.
  • 2 Neurology Section, Tibor Rubin VA Medical Center, Long Beach, CA, USA, akwang@uci.edu.
PMID: 31118583 DOI: 10.2147/DDDT.S162913
Abstract

Hereditary transthyretin amyloidosis is a fatal autosomal dominant disorder characterized by deposition of transthyretin amyloid into the peripheral nervous system, heart, kidney, and gastrointestinal tract. Previous treatments using liver transplantation and small molecule stabilizers were not effective in stopping disease progression. Inotersen, a 2'-O-methyoxyethyl-modified antisense oligonucleotide, which acts by reducing the production of transthyretin, was recently demonstrated to improve disease course and quality of life in early hereditary transthyretin amyloidosis polyneuropathy in a 15-month Phase III study.

Keywords

Inotersen; RNase H; antisense oligonucleotide; familial amyloid polyneuropathy; mRNA.

Figures
Products